Product image of Iruxol Mono (Collagenase Clostridium Histolyticum, Protease) supplied by GNH India

Iruxol Mono

Active Ingredient:
Collagenase Clostridium Histolyticum, Protease
Origin:
EU

Iruxol Mono (Collagenase Clostridium Histolyticum, Protease)

Collagenase Clostridium Histolyticum, the active ingredient in Iruxol, is a proteolytic enzyme presented as a topical formulation for cutaneous use. It enzymatically debrides necrotic tissue, facilitating wound healing in chronic wounds, pressure ulcers, diabetic foot ulcers, burns and traumatic skin lesions.

GNH India supplies Iruxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Customers benefit from reliable logistics, technical support, and compliance documentation.

Manufacturer / TM Owner

Smith & Nephew Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iruxol Mono, a collagenase enzyme, is used for enzymatic debridement of necrotic tissue in various wound types.

  • Chronic wounds: removal of necrotic tissue to promote granulation and healing.
  • Pressure ulcers: enzymatic breakdown of dead tissue to accelerate recovery.
  • Diabetic foot ulcers: facilitates debridement, supporting ulcer management.
  • Burns: assists in clearing eschar and necrotic layers for better regeneration.
  • Traumatic skin lesions: aids in selective removal of damaged tissue while preserving viable cells.

How It Works

  • Collagenase Clostridium Histolyticum hydrolyzes peptide bonds in collagen and other extracellular matrix proteins. By cleaving these structural components, the enzyme selectively dissolves necrotic tissue while sparing healthy tissue, thereby promoting the formation of granulation tissue and supporting the natural wound healing cascade.

Side Effects

Local application of Iruxol may cause reactions at the treatment site.

Common Side Effects

  • Redness or erythema at the application site.
  • Mild pain or burning sensation.
  • Swelling or edema.
  • Itching or pruritus.
  • Slight bleeding or oozing.
  • Increased wound exudate.

Serious or Rare Side Effects

  • Severe allergic reaction, including rash or hives.
  • Anaphylaxis requiring emergency care.
  • Cellulitis or secondary infection.
  • Deep tissue necrosis beyond intended area.
  • Systemic infection signs such as fever.
  • Persistent severe pain.

Precautions & Warnings

When using Iruxol, consider the following safety measures.

  • Assess wound suitability: ensure presence of necrotic tissue and no active infection.
  • Avoid use on healthy tissue: limit application to debridement areas only.
  • Monitor for local irritation: discontinue if severe redness or pain occurs.
  • Do not apply under occlusive dressings unless directed by a clinician.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Iruxol may interact with other agents applied to the wound.

Major Interactions (Avoid)

  • Concurrent use with other proteolytic enzymes: may increase tissue damage.
  • Use with systemic antibiotics: no direct interaction but monitor infection status.
  • Co‑administration with immunosuppressants: may impair wound healing.

Moderate Interactions (Monitor Closely)

  • Topical corticosteroids: may reduce enzyme activity and effectiveness.
  • Anticoagulants: increased risk of bleeding at the application site.

Frequently Asked Questions

Iruxol Mono is a topical enzymatic debriding agent containing collagenase that is applied to chronic wounds, pressure ulcers, diabetic foot ulcers, burns and traumatic skin lesions to selectively remove necrotic tissue and promote healing.

The collagenase enzyme hydrolyzes collagen and other extracellular matrix proteins in necrotic tissue. By breaking down these structural proteins, it loosens and dissolves dead tissue while preserving viable cells, facilitating natural wound repair processes.

The dosage and frequency of Iruxol Mono are determined by the prescribing clinician based on wound size, depth and patient condition. No fixed regimen is provided here; the prescriber will specify the appropriate amount and application schedule.

Safety data for Collagenase Clostridium Histolyticum in pregnancy or lactation are limited. Use only if the potential benefit justifies any potential risk, and the decision should be made by a qualified healthcare professional.

Submit an enquiry on the Iruxol Mono product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Iruxol provides enzymatic debridement, which is selective for necrotic tissue and can be less painful than mechanical or surgical methods. Compared with chemical agents, it offers targeted action with fewer systemic effects, though suitability depends on wound characteristics and clinical judgment.

Store Iruxol Mono at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid freezing to maintain enzyme stability.

Iruxol Mono is applied topically to the wound surface. The clinician cleans the area, spreads a thin layer of the product over necrotic tissue, and may cover it with a non‑occlusive dressing as directed. Application frequency is set by the prescriber.

Serious risks include severe allergic reactions such as anaphylaxis, deep tissue necrosis beyond the intended area, and secondary infections like cellulitis. Patients should be monitored for signs of systemic infection, worsening pain or extensive tissue damage.

Iruxol Mono should not be used on healthy, non‑necrotic skin, in patients with known hypersensitivity to collagenase or any formulation components, or on wounds with active uncontrolled infection unless directed by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Collagenase Clostridium Histolyticum, Protease

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT